Skip to main content
Psychiatry (Edgmont) logoLink to Psychiatry (Edgmont)
letter
. 2007 Jul;4(7):18–19.

EEG Abnormalities in a patient taking Aripiprazole

Monica Arora 1,, Laurie Arndorfer 2
PMCID: PMC2880927  PMID: 20526402

Dear Editor:

Aripiprazole is a second generation antipsychotic and works as a partial agonist at dopamine and serotonin 5-HT1A receptors and a partial antagonist at serotonin 5HT2A receptors. Commonly experienced side effects of this medication include constipation, akathisia, extrapyramidal side effects, sedation, tremor, and restlessness.1

In rare instances, aripiprazole has been implicated in causing seizures or convulsions. Preclinical marketing studies by manufacturer Bristol-Myers Squibb for aripiprazole found an incidence of seizure at 0.1 percent of patients treated with this medication for schizophrenia and 0.3 percent of patients treated for bipolar mania.2 In addition, in a literature search, we have identified two case reports of aripiprazole-induced seizure.3,4 Electroencephalogram (EEG) abnormalities have been noted to occur with use of both typical and atypical antipsychotics,5 though no case reports implicating aripiprazole were found in the literature search. We report a case in which EEG anomalies occurred in a patient treated with aripiprazole.

Case report. Mr. H. is a 13-year-old Caucasian adolescent boy with a history of disruptive behavior disorder and depressive disorder, NOS, with significant out of control behavior at home and school. Past medication trials included methylphenidate hydrochloride, clonidine, risperidone, and bupropion without much improvement of symptoms, hence all medications were discontinued by his outpatient provider. Three weeks later, the patient was started on aripiprazole (10mg per day) to help control the patient's agitation and impulsive aggression.

During the follow-up visit, four weeks later, Mr. H's mother reported new onset staring spells and episodes where the patient's hands seemed to twitch and then stiffen for several seconds at a time. At that time, Mr. H's outpatient psychiatrist recommended an EEG. The EEG showed “generalized epilepsy,” though Mr. H was never noted to have full blown tonic-clonic movements or impairment of consciousness. The patient was continued on aripiprazole 10mg for another month. Another EEG was completed four weeks later, which again showed “seizure activity.” Aripiprazole was then discontinued, as no other medical cause for the Mr. H's EEG abnormalities could be found. Mr. H's staring spells and hand twitching abruptly ceased after discontinuation of aripiprazole.

Increase in intensity and frequency of Mr. H's outbursts after discontinuing aripiprazole led to his hospitalization three weeks later. Thorough medical workup was completed and results were within normal limits. A pediatric neurologist was consulted and the EEG was repeated within a week of his hospitalization, which showed no seizure activity. The previous EEG abnormalities were then attributed to medication effect.

Discussion. The incidence of seizure associated with second generation antipsychotic medications is well documented in the literature, especially with clozapine.6 Several factors are associated with an increased risk, including a family history of seizure disorder, head trauma, and concomitant use of medications known to lower the seizure threshold. None of these risk factors were present in Mr. H. Other medical causes for this patient's EEG abnormalities were ruled out, and there were no other implicated medications.

Since experience with aripiprazole is limited at this time, the risk of EEG abnormalities and potentially the risk of lowering the seizure threshold with this drug requires further investigation.

With regards,
Monica Arora MD
Assistant Professor, Creighton University, Department of Psychiatry, Omaha, Nebraska

Laurie Arndorfer, MD
Second Year Psychiatry Resident CU/UMNC Psychiatry Program, Omaha, Nebraska

Contributor Information

Monica Arora, Assistant Professor, Creighton University, Department of Psychiatry, Omaha, Nebraska.

Laurie Arndorfer, Second Year Psychiatry Resident, CU/UMNC Psychiatry Program, Omaha, Nebraska.

References

  • 1.Swainston HT, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715–36. doi: 10.2165/00003495-200464150-00010. [DOI] [PubMed] [Google Scholar]
  • 2.Physician's Desk Reference. 61st. Montvale, NJ: Medical Economics; 2006. Prescribing information for aripiprazole. [Google Scholar]
  • 3.Tsai J. Aripiprazole-associated seizure. J Clin Psychiatry. 2006;67(6):995–6. doi: 10.4088/jcp.v67n0619b. [DOI] [PubMed] [Google Scholar]
  • 4.Malik AR, Ravasia S. Aripiprazole-induced seizure. Can J Psychiatry. 2005;50(3):186. doi: 10.1177/070674370505000318. [DOI] [PubMed] [Google Scholar]
  • 5.Centorrino F, Price B, Tuttle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry. 2002;159:109–15. doi: 10.1176/appi.ajp.159.1.109. [DOI] [PubMed] [Google Scholar]
  • 6.Welch J, Manschrek T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatr Clin Neurosci. 1994;6(3):250–6. doi: 10.1176/jnp.6.3.250. [DOI] [PubMed] [Google Scholar]

Articles from Psychiatry (Edgmont) are provided here courtesy of Matrix Medical Communications

RESOURCES